SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors digest news regarding preliminary Q1 revenue falling short of guidance, attributed to design upgrades pushing revenue to Q2. Despite the setback, the company reiterated its full-year revenue guidance, sparking debate among investors about management's credibility and the potential for future growth in the AI sector. Community discussions revolve around whether this is a buying opportunity or a sign of deeper issues within the company.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid reports of the Trump administration considering equity stakes in quantum computing firms, sparking excitement and volatility. The community is debating the legitimacy and potential impact of government involvement in the sector. Discussions also include the broader implications for quantum computing and comparisons to other tech industries.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon (VZ) is trending as investors weigh the stock's potential amid upcoming earnings and a recent analyst downgrade. Community chatter revolves around whether the stock is oversold, with some anticipating a double bottom bounce, while others express concerns about earnings and the dividend's sustainability. Many are also discussing the potential impact of competition from T-Mobile and the broader telecom sector dynamics.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

VTYX is trending as positive trial results spark optimism around the stock's potential, with some community members speculating about a possible Sanofi buyout. Bullish investors are actively discussing potential price upgrades and high price targets. However, some traders remain cautious, pointing to potential short attacks and the possibility of a retracement.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors debate the likelihood of EMA approval for Blarcamesine, its Alzheimer's drug candidate, with a decision expected soon. Community discussions revolve around the potential for a short squeeze and the impact of analyst opinions, particularly regarding the drug's commercial prospects. Some traders are also pointing to recent analyst's "hit piece" as coordinated FUD to cover shorts.

Integer Holdings Corp. engages in the manufacture and development of medical devices and components. The firm has the following product lines: Cardio and Vascular, Cardiac Rhythm Management and Neuromodulation, and Other Markets. The company was founded by Wilson Greatbatch in 1970 and is headquartered in Plano, TX.

Integer Holdings Corp

Integer Holdings ($ITGR) is trending due to a significant price drop, sparking discussions about market manipulation and potential overreaction to recent results, despite beating Q3 estimates. The community is actively debating whether this dip represents a buying opportunity, with some citing the company's strong institutional ownership as a factor for potential rebound. Analyst ratings have recently been updated, adding to the mixed sentiment surrounding the stock's future.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a recent partnership with Anthropic to integrate AI models into IBM software, sparking optimism around its AI capabilities. The community is also discussing IBM's leadership in quantum computing and its potential for long-term growth. Despite some mixed reactions, analysts maintain a positive outlook, emphasizing IBM's strategic position in both the AI and quantum sectors.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is seeing active discussion, with community members reacting to recent performance and analyst target price adjustments. Some traders are weighing short-term opportunities, while others debate the company's long-term vision, particularly around AI and full self-driving, as well as Musk's leadership and proposed compensation.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

SLMT is trending due to recent news regarding its Solana validator operations, data center selection in the UAE, and M&A strategy. The community is discussing potential price targets, a possible short squeeze, and the stock's correlation with Solana's performance. Some investors believe it's undervalued, while others are wary of potential dilution.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as the community discusses the potential for government quantum investments and its strategic policy shift. Bullish investors are noting the company's strong cash position and potential for a short squeeze, while bearish investors cite concerns about overvaluation and sector hype. Overall, the conversation is centered around the potential impact of government involvement in the quantum computing sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy

Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical...

Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's  What You Should Know

Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment surged following news of an upcoming presentation linked to its lead drug candidate.&nbsp;The clinical-stage biopharma company, which is developing novel therapeutics targeting metabolic and fibrotic diseases, announced that it will present at the 9th Annual MASH-TAG Conference in Park City, Utah, from Jan. 9&nbsp;to 11.The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b FASCINATE-2 study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMT_sentiment_and_message_volume_Jan_6_fc5e3fb3e0.png" alt="SGMT sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>SGMT sentiment and message volume Jan 6 as of 11:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish,’ with Sagimet’s stock trending among the top 20 tickers as of mid-morning.&nbsp;Many investors&nbsp;eagerly await further announcements at the conference, with some buying based on rumors of a significant update.<stembedurl>https://stocktwits.com/GXD_Texas/message/598950606</stembedurl><stembedurl>https://stocktwits.com/valueforme/message/598944787</stembedurl>The study demonstrated a positive anti-fibrotic effect, providing strong support for the drug’s potential in treating liver diseases caused by excessive fat buildup and inflammation.Sagimet’s FASN inhibitors aim to address the dysfunctional metabolic pathways responsible for the overproduction of palmitate, a fatty acid linked to diseases like MASH.&nbsp;Denifanstat’s progress has been noteworthy, with Breakthrough Therapy designation granted by the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3).Oppenheimer’s recent coverage of Sagimet with an ‘outperform’ rating and a $30 price target, which implies more than a 340% upside from current levels, has also contributed to the stock’s upward movement.&nbsp;The brokerage firm highlighted denifanstat’s potential in the MASH market, which is currently dominated by Madrigal Pharmaceuticals’ Resmetirom.&nbsp;Oppenheimer estimates denifanstat could achieve peak revenues of around $1.9 billion by 2040, solidifying its long-term growth prospects.<a href="https://stocktwits.com/symbol/SGMT">Sagimet stock</a> has gained nearly 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate

Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.

Equity

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc